Hyperimmune

Twist Bioscience Highlights Synthetic Libraries and High Throughput Antibody Discovery Platform at PEGS Boston 2022

Retrieved on: 
Monday, May 2, 2022
Health, Biotechnology, CAR, Antibody, Proteinogenic amino acid, Epitope, VHH, U.S. Securities and Exchange Commission, Forward-looking statement, Private Securities Litigation Reform Act, Hynes Convention Center station, Agriculture, Immunoglobulin G, RNA transfection, Library, NASDAQ, SVP, Phoenix Carnegie Library and Library Park, Engineering, Martek Biosciences Corporation, Cell, NGS, Doctor of Philosophy, Patient, Twist Bioscience, Drug discovery, Gene editing, Risk, PEGS, ELISA, Therapy, Synthetic biology, Aircraft registration, Concurrent use registration, DNA, Genomics, ADORA2A, Hynes Convention Center, Security (finance), Silicon, TCR, Immunization, CRISPR, SEC, Hyperimmune, CEO, Protein, Technology, Biology, Humanized antibody, Vaccine, Antibiotics

These posters show the depth and breadth of the antibody discovery and library construction capabilities of Twist Biopharma against high-impact targets, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Key Points: 
  • These posters show the depth and breadth of the antibody discovery and library construction capabilities of Twist Biopharma against high-impact targets, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • Our next generation libraries enable antibody discovery for therapies such as CAR-T engineered cell therapies, which have the potential to change the treatment landscape for patients.
  • In addition, the data presented on the discovery of an antibody targeting ADORA2A, a next generation checkpoint, demonstrate Twist Biopharmas ability to generate antibodies independently.
  • Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development.

COVID-19 Treatment Clinical Landscape Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 9, 2021
Health, Pharmaceutical, Medicine, Clinical medicine, Medical specialties, Antiviral drug, Biocides, Hyperimmune, Immunology, Immunotherapy, COVID-19, Monoclonal antibody

The "Disease Analysis: COVID-19 Treatment" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: COVID-19 Treatment" report has been added to ResearchAndMarkets.com's offering.
  • The commercial outlook for COVID-19 therapeutics is expected to decline progressively throughout 2021 due to the phased implementation of global vaccination programs, which should substantially reduce both outpatient and hospital COVID-19 cases.
  • Veklury faces myriad threats from pipeline candidates, including antivirals, immunomodulatory agents, monoclonal antibodies, and hyperimmune globulin therapies.
  • The overall likelihood of approval of a Phase I antiviral asset is 12.9%, and the average probability a drug advances from Phase III is 68.5%.

CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine

Retrieved on: 
Friday, April 2, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Clinical trials, Other Health, Medicine, Clinical medicine, Branches of biology, Emergent BioSolutions, Hyperimmune globulin, Behring, Grifols, Hyperimmune, Severe acute respiratory syndrome, the ITAC Trial, the CoVIg-19 Plasma Alliance

Analyses remain ongoing and NIAID and the INSIGHT Network intend to publish the full results of the trial soon.

Key Points: 
  • Analyses remain ongoing and NIAID and the INSIGHT Network intend to publish the full results of the trial soon.
  • Since we embarked on this development program, and throughout the pandemic, we have learned much from our scientific research.
  • Four companies provided investigational H-Ig materials for the trial, including CSL Behring and Takeda on behalf of the CoVIg-19 Plasma Alliance, as well as Emergent BioSolutions and Grifols.
  • The Alliance brought together world-leading plasma companies to work on the development of an investigational unbranded polyclonal anti-SARS-CoV-2 hyperimmune globulin medicine intended for the treatment of patients at risk for serious complications from COVID-19.

Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE™) at The 62nd Annual Society of Hematology (ASH) Meeting

Retrieved on: 
Monday, November 30, 2020
Clinical medicine, Medicine, Branches of biology, Glycoproteins, Immunology, Cancer immunotherapy, Antibodies, Hyperimmune, Immunotherapy

Data will be presented at the upcoming 62nd American Society for Hematology (ASH) annual meeting, being held in a virtual format December 5- 8, 2020.

Key Points: 
  • Data will be presented at the upcoming 62nd American Society for Hematology (ASH) annual meeting, being held in a virtual format December 5- 8, 2020.
  • Details of the electronic presentation are as follows:
    Kleos MATE platform enables site-directed chemical conjugation with off-the-shelf therapeutic antibodies to rapidly add or improve functionality to existing therapies.
  • In addition to oncology applications, the MATE platform is also being used to develop Kleos COVID-19 hyperimmune globulin mimic (HGM) therapy.
  • Kleo Pharmaceuticals is a targeted immunotherapy company that develops fully synthetic bispecific therapies to redirect, enhance or replace antibodies.

Rallybio Announces First-in-Human Dosing in RLYB211 Phase 1/2 Study

Retrieved on: 
Tuesday, November 10, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Blood, Transfusion medicine, Antibodies, Human platelet antigen, Platelet, Hyperimmune globulin, Hyperimmune, FNAIT, RLYB211, Rallybio

Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that dosing has commenced in a Phase 1/2 study evaluating RLYB211, a plasma-derived hyperimmune globulin, in healthy male participants.

Key Points: 
  • Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that dosing has commenced in a Phase 1/2 study evaluating RLYB211, a plasma-derived hyperimmune globulin, in healthy male participants.
  • The Phase 1/2 study is a single-blind, placebo-controlled proof-of-concept study designed to establish the dose of RLYB211 that will rapidly clear HPA-1a positive platelets transfused to HPA-1a negative healthy male participants.
  • The study consists of three cohorts, each investigating a different dose of RLYB211.
  • Additional information on the RLYB211 Phase 1/2 study is available at clinicaltrialsregister.eu with EudraCT Number 2019-003459-12.

CSL's Broad Response to COVID-19 and Advancements across the Company's Strategic Scientific Platforms are the Focus of Annual R&D Day

Retrieved on: 
Tuesday, October 20, 2020
Sarbecovirus, Respiratory diseases, Zoonoses, Animal diseases, CSL Limited, Hyperimmune, Health, Behring, Coronavirus disease, Severe acute respiratory syndrome

It's this scientific capability and diverse portfolio that positioned the company to quickly respond to the COVID-19 public health crisis.

Key Points: 
  • It's this scientific capability and diverse portfolio that positioned the company to quickly respond to the COVID-19 public health crisis.
  • Co-founding theCoVIg-19 Plasma Alliance, an unprecedented industry partnership of more than 12 plasma industry companies, to develop a hyperimmune for treating COVID-19.
  • Developing an investigational, anti-SARS-CoV-2 plasma hyperimmune product for the Australian market to treat people with serious complications of COVID-19.
  • Today, CSL including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 70 countries and employs 27,000 people.

Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19

Retrieved on: 
Thursday, October 8, 2020
Health, Medicine, Clinical medicine, Antibodies, Antivirals, Glycoproteins, Hyperimmune globulin, Clinical research, Pharmaceutical industry, Remdesivir, Hyperimmune, Coronavirus disease

We are drawing from decades of experience developing treatments on our well-established hyperimmune platform to address this serious public health threat.

Key Points: 
  • We are drawing from decades of experience developing treatments on our well-established hyperimmune platform to address this serious public health threat.
  • Emergent is one of four companies providing hyperimmune globulin products for the trial, which plans to enroll approximately 500 patients across U.S. and international clinical trial sites.
  • The main goal of the trial is to compare the health status of participants treated with hyperimmune globulin plus remdesivir with participants treated with a placebo plus remdesivir.
  • Using its established hyperimmune platforms, Emergent is developing two investigational plasma-based treatments - COVID-19 Human Immune Globulin (COVID-HIG) and COVID-Equine Immune Globulin (COVID-EIG).

Plasma Fractionation Market Worth $41.4 billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis by Meticulous Research®

Retrieved on: 
Thursday, September 10, 2020
Branches of biology, Anatomy, Blood, Body fluids, Medical technology, Transfusion medicine, Blood plasma, Hyperimmune globulin, Hyperimmune, Fractionation, Plasma

Limited data is available to suggest that convalescent plasma and hyperimmune globulin may have benefits in the COVID-19 illness.

Key Points: 
  • Limited data is available to suggest that convalescent plasma and hyperimmune globulin may have benefits in the COVID-19 illness.
  • Based on the end user, hospitals and clinics segment is estimated to command the largest share of the overall plasma fractionation market in 2020.
  • Quick Buy Plasma Fractionation Market Research Report: https://www.meticulousresearch.com/buy_now.php?pformat=421&vformat=1249
    Geographically, North America estimated to dominate the global plasma fractionation market in 2020, followed by Europe and Asia-Pacific.
  • The plasma fractionation market has witnessed a number of new product launches; partnership, agreements, & collaborations; expansions; and acquisitions.

Plasma Fractionation Market Worth $41.4 billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis by Meticulous Research®

Retrieved on: 
Thursday, September 10, 2020
Branches of biology, Anatomy, Blood, Body fluids, Medical technology, Transfusion medicine, Blood plasma, Hyperimmune globulin, Hyperimmune, Fractionation, Plasma

Limited data is available to suggest that convalescent plasma and hyperimmune globulin may have benefits in the COVID-19 illness.

Key Points: 
  • Limited data is available to suggest that convalescent plasma and hyperimmune globulin may have benefits in the COVID-19 illness.
  • Based on the end user, hospitals and clinics segment is estimated to command the largest share of the overall plasma fractionation market in 2020.
  • Quick Buy Plasma Fractionation Market Research Report: https://www.meticulousresearch.com/buy_now.php?pformat=421&vformat=1249
    Geographically, North America estimated to dominate the global plasma fractionation market in 2020, followed by Europe and Asia-Pacific.
  • The plasma fractionation market has witnessed a number of new product launches; partnership, agreements, & collaborations; expansions; and acquisitions.

Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding

Retrieved on: 
Wednesday, July 8, 2020
Food and Drug Administration, United States Public Health Service, Sinai, Hyperimmune, Health, Articles, Food and Drug Administration, United States Public Health Service, Sinai, Hyperimmune, Health, Articles

The collaborators will establish plasma collection capabilities at Mount Sinai through an extension of ImmunoTeks FDA-approved establishment license and the transfer of technical know-how to Mount Sinai.

Key Points: 
  • The collaborators will establish plasma collection capabilities at Mount Sinai through an extension of ImmunoTeks FDA-approved establishment license and the transfer of technical know-how to Mount Sinai.
  • The front-line health care workers and others who protect us are a top priority for reducing the impact of COVID-19.
  • Emergent is drawing from decades of experience with our human hyperimmune platform, on which several products have been FDA-licensed, to develop COVID-HIG.
  • This unprecedented public health crisis is a critical moment for Americans to donate plasma, said Jerome Parnell III, CEO and President, ImmunoTek Bio Centers.